On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma : an early 2022 glance into the future
INTRODUCTION: The pace at which the identification of novel therapeutic targets has led to the approval of multiple myeloma (MM) agents during the last two decades is nothing more than spectacular. Nevertheless, MM remains an incurable disease. Therefore, there is an urgent need for additional, innovative therapeutics. Immune dysfunction and the tumor-permissive immune bone marrow microenvironment represent hallmarks of MM pathophysiology. Naked monoclonal antibodies directed against SLAMF7 and CD38 already constitute backbones of today's MM therapy. Novel immunotherapeutic modalities including antibody-drug-conjugates (ADC), bispecific antibodies (BsAb), and chimeric-antigen-receptor T cells are on the way to once more revolutionize future MM therapy.
AREAS COVERED: The present review article summarizes the most recent results on MM immunotherapies presented at the 2021 Annual Meeting of the American Society of Hematology; and throws a glance on ongoing preclinical and clinical efforts aiming at further increasing their efficacy, while reducing their toxicity.
EXPERT OPINION: With the approvals of the first-in-class BCMA-targeting ADC (belantamab mafodotin) and two BCMA-targeting CAR T cell products (Ide-cel, Cilta-cel); and the approval of the first-in-class BCMAxCD3 BsAb immediately pending, the era of modern next-generation immunotherapies in MM is continuously evolving. Long-term disease-free survival and potential cure of MM are finally within reach.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Expert opinion on pharmacotherapy - 23(2022), 12 vom: 06. Aug., Seite 1425-1444 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sunder-Plassmann, Vincent [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.08.2022 Date Revised 08.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14656566.2022.2101362 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343499916 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343499916 | ||
| 003 | DE-627 | ||
| 005 | 20231226020603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14656566.2022.2101362 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343499916 | ||
| 035 | |a (NLM)35829636 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sunder-Plassmann, Vincent |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma |b an early 2022 glance into the future |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2022 | ||
| 500 | |a Date Revised 08.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The pace at which the identification of novel therapeutic targets has led to the approval of multiple myeloma (MM) agents during the last two decades is nothing more than spectacular. Nevertheless, MM remains an incurable disease. Therefore, there is an urgent need for additional, innovative therapeutics. Immune dysfunction and the tumor-permissive immune bone marrow microenvironment represent hallmarks of MM pathophysiology. Naked monoclonal antibodies directed against SLAMF7 and CD38 already constitute backbones of today's MM therapy. Novel immunotherapeutic modalities including antibody-drug-conjugates (ADC), bispecific antibodies (BsAb), and chimeric-antigen-receptor T cells are on the way to once more revolutionize future MM therapy | ||
| 520 | |a AREAS COVERED: The present review article summarizes the most recent results on MM immunotherapies presented at the 2021 Annual Meeting of the American Society of Hematology; and throws a glance on ongoing preclinical and clinical efforts aiming at further increasing their efficacy, while reducing their toxicity | ||
| 520 | |a EXPERT OPINION: With the approvals of the first-in-class BCMA-targeting ADC (belantamab mafodotin) and two BCMA-targeting CAR T cell products (Ide-cel, Cilta-cel); and the approval of the first-in-class BCMAxCD3 BsAb immediately pending, the era of modern next-generation immunotherapies in MM is continuously evolving. Long-term disease-free survival and potential cure of MM are finally within reach | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Car T-cells | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a antibody-drug-conjugates | |
| 650 | 4 | |a bispecific antibodies | |
| 650 | 4 | |a monoclonal antibodies | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a B-Cell Maturation Antigen |2 NLM | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a idecabtagene vicleucel |2 NLM | |
| 650 | 7 | |a 8PX1X7UG4D |2 NLM | |
| 700 | 1 | |a Aksoy, Osman |e verfasserin |4 aut | |
| 700 | 1 | |a Lind, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Pecherstorfer, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Vallet, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Podar, Klaus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on pharmacotherapy |d 1999 |g 23(2022), 12 vom: 06. Aug., Seite 1425-1444 |w (DE-627)NLM111602130 |x 1744-7666 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:12 |g day:06 |g month:08 |g pages:1425-1444 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14656566.2022.2101362 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 12 |b 06 |c 08 |h 1425-1444 | ||